Pharmaceutical company AstraZeneca has launched a global trial to test the effectiveness of Calquence, currently used to treat lyphoma and leukemia, in Covid-19 patients.
The company will trial whether Calquence, a brand name of the drug acalabrutinib, could treat the hyperactive immune response associated with severe Covid-19. AstraZeneca’s executive vice president of research & development oncology José Baselga said the company hopes to demonstrate “that adding Calquence to best supportive care reduces the need to place patients on ventilators and improves their chances of survival”.
Read the full story at Pharmaceutical Technology.
Treat yourself or a friend this Christmas to a New Statesman subscription for just £2
Content from our partners
Related
